The Feasibility and Pharmacokinetics of Intensive Therapy for Rheumatoid Arthritis using Methotrexate Loading: A 6-week randomised clinical trial.

Central Adelaide Local Health Network Incorporated0 个研究点目标入组 20 人开始时间: 2023年4月28日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•Patients attending the rheumatology clinic at the Central Adelaide Local Health Network (CALHN) who have active rheumatoid arthritis and for whom the decision has been made to commence methotrexate (and sulfasalazine and hydroxychloroquine) as triple DMARD therapy.
•The decision to use methotrexate is not part of this trial. It will be made according to clinical need and according to our standardised inclusion criteria for commencement of methotrexate therapy. These include:
•1) ALT < 2x ULN
•2) Calculated Creatinine Clearance > 60 mL/min (Cockcroft-Gault)
•3) Neutrophils within normal range
•4) If a smoker, Pulmonary Function Tests will be conducted, and they must have FVC>70% predicted and DLCO> 60% predicted
•5) At least 5 years since treatment for a malignancy (except non-melanoma skin cancers)
•6) Not pregnant (test is done as standard prior to MTX commencement)
•7) Able to read English and/or good communication skills.
•8) Age greater than or equal to 18 years

•1) BMI < 18 because sub-cutaneous injections of MTX will be used in the loading dose group. An upper BMI was discussed but there is no apparent reason for specifying an upper limit.
•2) Age > 85 years

发起方